|
Collaboration Arrangements - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified |
3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 32 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2014
|
Sep. 30, 2013
|
Sep. 30, 2014
|
Sep. 30, 2013
|
Mar. 31, 2014
Merck KGaA
|
Sep. 30, 2014
Merck KGaA
|
Sep. 30, 2014
Merck KGaA
|
Sep. 30, 2014
Merck KGaA
United States
|
Sep. 30, 2014
Merck KGaA
Regulatory and Development Milestones
|
Sep. 30, 2014
Merck KGaA
Commercialization Milestones
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
| Upfront and milestone payments received to date | $ 12.5 | $ 110.0 | ||||||||
| Potential future milestones | 100 | 340 | ||||||||
| Merck KGaA's percentage share of worldwide development expenses | 70.00% | |||||||||
| Portion of profits that Company is eligible to participate, depending upon total sales | 50.00% | |||||||||
| Revenue recognized by the Company | 3.7 | 3.2 | 11.0 | 9.3 | ||||||
| Company earned a reimbursement for eligible worldwide development expenses | $ 4.8 | $ 5.5 | $ 14.2 | $ 11.6 | ||||||